{'fraction_non_alphanumeric': 0.012465373961218837, 'fraction_numerical': 0.006925207756232687, 'mean_word_length': 5.398230088495575, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
An early intervention secondary prevention study with oxprenolol following myocardial infarction.

A randomised double–blind placebo controlled trial was designed to evaluate the efficacy of oxprenolol 40 mg b.d. in the prevention of cardiac events between 2–56 days following uncomplicated acute myocardial infarction. Three hundred and thirteen male and female patients were recruited over three years; the study was terminated when it became evident that a conclusive result could not be obtained within any reasonable extension of the planned trial duration. This was largely due to the better than expected prognosis of selected patients. Our study highlights some of the difficulties in clinical trials in this field